^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ABSK121

    i
    Other names: ABSK121, ABSK121-NX, ABSK 121, ABSK121 NX, ABSK-121, ABSK121NX
    Company:
    Abbisko
    Drug class:
    pan-FGFR inhib
    over1year
    A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=169, Recruiting, Abbisko Therapeutics Co, Ltd | Not yet recruiting --> Recruiting | Initiation date: Dec 2022 --> Jun 2023
    Enrollment open • Trial initiation date • Metastases
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR3 S249C • FGFR2 rearrangement • FGFR3 Y373C • FGFR3 G370C • FGFR3 R248C
    |
    ABSK121
    2years
    A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=169, Not yet recruiting, Abbisko Therapeutics Co, Ltd
    New P1 trial • Metastases
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR3 S249C • FGFR2 rearrangement • FGFR3 Y373C • FGFR3 G370C • FGFR3 R248C
    |
    ABSK121